Fresh analysis indicates that individuals who stop using new slimming jabs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who halt conventional lifestyle plans.
Findings released in a leading medical journal points out that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users purchasing such drugs must be informed of the danger of rapid rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain means a return to starting mass within about one and a half years.
Weighing Approaches
The research, which examined dozens of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through diet and exercise typically see a slower creep back—approximately 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Experts suggest the mode of action of the jabs explains the amplified regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement results in appetite is uncontrolled, making binge eating a significant risk."
A Chronic Disease?
The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals contend that, given the high risk of relapse, the therapy should be considered long-term.
This view is echoed by drug manufacturers, who state that the results "emphasize the chronic nature of excess weight," similar to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the jabs report a powerful return of cravings.
"I experienced a trigger flipping and you're instantly starving," recalled an individual.
This challenge is exacerbated if individuals have not established permanent lifestyle or habit modifications during therapy.
Growing Interest
Figures show that a significant number of adults in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is more common among females compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent agents for weight loss, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural changes.
